Geron Corporation (NASDAQ:GERN) Director Daniel Bradbury purchased 142,776 shares of the stock in a transaction dated Friday, May 9th. The stock was purchased at an average cost of $1.75 per share, for a total transaction of $249,858.00. Following the completion of the purchase, the director now directly owns 142,776 shares in the company, valued at approximately $249,858. Geron Corporation (NASDAQ:GERN) weekly performance is-1.06%. On last trading day company shares ended up $1.86. Analysts mean target price for the company is $2.00. Geron Corporation (NASDAQ:GERN) distance from 50-day simple moving average (SMA50) is -22.49%.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Michael Porter purchased 10,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average cost of $6.59 per share, for a total transaction of $65,900.00. Following the acquisition, the director now directly owns 520,865 shares in the company, valued at approximately $3,432,500. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares advanced 1.35% in last trading session and ended the day on $6.77. MACK return on assets is -80.10%. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) quarterly performance is 38.45%.
Aegerion Pharmaceuticals Inc (NASDAQ:AEGR) Director Anne Vanlent bought 4,000 shares of the stock in a transaction dated Thursday, May 8th. The shares were purchased at an average cost of $33.78 per share, for a total transaction of $135,120.00. Following the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $135,120. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares moved up 0.43% in last trading session and was closed at $32.76, while trading in range of $31.77 – $34.15. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) year to date (YTD) performance is -53.83%.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel Bradbury bought 138,925 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $1.80 per share, with a total value of $250,065.00. Corcept Therapeutics Incorporated (NASDAQ:CORT) ended the last trading day at $1.85. Company weekly volatility is calculated as 11.26% and price to cash ratio as 3.39. Corcept Therapeutics Incorporated (NASDAQ:CORT) showed a negative weekly performance of-55.42 %.